{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:28:06Z","timestamp":1784561286805,"version":"3.55.0"},"reference-count":43,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,2]]},"abstract":"ABSTRACT<\/jats:title>\n \n Omadacycline is the first intravenous and oral 9-aminomethylcycline in clinical development for use against multiple infectious diseases including acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), and urinary tract infections (UTI). The comparative\n in vitro<\/jats:italic>\n activity of omadacycline was determined against a broad panel of Gram-positive clinical isolates, including methicillin-resistant\n Staphylococcus aureus<\/jats:named-content>\n (MRSA), vancomycin-resistant\n Enterococcus<\/jats:named-content>\n (VRE), Lancefield groups A and B beta-hemolytic streptococci, penicillin-resistant\n Streptococcus pneumoniae<\/jats:named-content>\n (PRSP), and\n Haemophilus influenzae<\/jats:named-content>\n (\n H. influenzae<\/jats:named-content>\n ). The omadacycline MIC\n 90<\/jats:sub>\n s for MRSA, VRE, and beta-hemolytic streptococci were 1.0 \u03bcg\/ml, 0.25 \u03bcg\/ml, and 0.5 \u03bcg\/ml, respectively, and the omadacycline MIC\n 90<\/jats:sub>\n s for PRSP and\n H. influenzae<\/jats:named-content>\n were 0.25 \u03bcg\/ml and 2.0 \u03bcg\/ml, respectively. Omadacycline was active against organisms demonstrating the two major mechanisms of resistance, ribosomal protection and active tetracycline efflux.\n In vivo<\/jats:italic>\n efficacy of omadacycline was demonstrated using an intraperitoneal infection model in mice. A single intravenous dose of omadacycline exhibited efficacy against\n Streptococcus pneumoniae<\/jats:named-content>\n ,\n Escherichia coli<\/jats:named-content>\n , and\n Staphylococcus aureus<\/jats:named-content>\n , including\n tet<\/jats:italic>\n (M) and\n tet<\/jats:italic>\n (K) efflux-containing strains and MRSA strains. The 50% effective doses (ED\n 50<\/jats:sub>\n s) for\n Streptococcus pneumoniae<\/jats:named-content>\n obtained ranged from 0.45 mg\/kg to 3.39 mg\/kg, the ED\n 50<\/jats:sub>\n s for\n Staphylococcus aureus<\/jats:named-content>\n obtained ranged from 0.30 mg\/kg to 1.74 mg\/kg, and the ED\n 50<\/jats:sub>\n for\n Escherichia coli<\/jats:named-content>\n was 2.02 mg\/kg. These results demonstrate potent\n in vivo<\/jats:italic>\n efficacy including activity against strains containing common resistance determinants. Omadacycline demonstrated\n in vitro<\/jats:italic>\n activity against a broad range of Gram-positive and select Gram-negative pathogens, including resistance determinant-containing strains, and this activity translated to potent efficacy\n in vivo<\/jats:italic>\n .\n <\/jats:p>","DOI":"10.1128\/aac.01242-13","type":"journal-article","created":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T05:31:23Z","timestamp":1386048683000},"page":"1127-1135","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":166,"title":["In Vitro<\/i>\n and\n In Vivo<\/i>\n Antibacterial Activities of Omadacycline, a Novel Aminomethylcycline"],"prefix":"10.1128","volume":"58","author":[{"given":"A. B.","family":"Macone","sequence":"first","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. K.","family":"Caruso","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. G.","family":"Leahy","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Donatelli","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Weir","sequence":"additional","affiliation":[{"name":"Boston University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P.","family":"Draper","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K.","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. B.","family":"Levy","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.6.1523"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.65.2.232-260.2001"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01402-10"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4892(01)00081-9"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.4.738"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01288-13"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/B0-08-045044-X\/00221-2","volume-title":"Comprehensive medicinal chemistry II","author":"Nelson ML","year":"2007","unstructured":"NelsonMLIsmailMY. 2007. The Antibiotic and Nonantibiotic Tetracyclines, p 597\u2013617. In TaylorJBTriggleDJ (ed), Comprehensive medicinal chemistry II, vol 7. Therapeutic areas II: cancer infectious diseases, inflammation and immunology and dermatology. Elsevier, Oxford, United Kingdom."},{"key":"e_1_3_2_9_2","volume-title":"Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Bhatia B","year":"2003","unstructured":"BhatiaBBowserTChenJIsmailMMcIntyreLMechicheRNelsonMOhemengKVermaAJonesGFallonM. 2003. PTK 0796 and other novel tetracycline derivatives exhibiting potent in vitro and in vivo activities against antibiotic resistant gram-positive bacteria, abstr 2420, poster F-755. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_10_2","volume-title":"Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Biedenbach DJ","year":"2010","unstructured":"BiedenbachDJMendesRESaderHSJonesRN. 2010. In vitro evaluation of PTK796 activity tested against Staphylococcus aureus, including hospital- and community-associated MRSA strains from the U. S. A. and Europe, abstr E-1569. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_11_2","volume-title":"Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Dubois J","year":"2006","unstructured":"DuboisJTanakaSK. 2006. In vitro activity of MK-2764\/PTK 0796 against Legionella spp., abstr 1846, poster F1-1974. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_12_2","volume-title":"Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Macone A","year":"2003","unstructured":"MaconeADonatelliJDumontTLevySBTanakaSK. 2003. In vitro activity of PTK 0796 against gram-positive and gram-negative organisms, abstr 2439, poster F-754. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_13_2","volume-title":"Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Macone AB","year":"2010","unstructured":"MaconeABArbeitRDHaitHIDraperMPTanakaSK. 2010. Identification and susceptibility of pathogens isolated from patients with complicated skin and skin structure infections (cSSSI): results of a PTK796 (PTK) phase 2 clinical trial, abstr 3178, poster L1-1760. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_14_2","volume-title":"Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Sader HS","year":"2010","unstructured":"SaderHSMendesREBiedenbachDJJonesRN. 2010. Antimicrobial activity of PTK796 tested against gram-positive organisms causing bloodstream infections in 2009, abstr E-1588. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_15_2","volume-title":"Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Smith K","year":"2006","unstructured":"SmithKTanakaSKAppelbaumPC. 2006. Antistaphylococcal activity of MK-2764\/PTK 0796 compared to other agents, abstr 1860, poster F1-1971. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_16_2","volume-title":"Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Traczewski MM","year":"2003","unstructured":"TraczewskiMMBrownSD. 2003. PTK 0796: In vitro potency and spectrum of activity compared to ten other antimicrobial compounds, abstr 2458, poster F-753. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_17_2","volume-title":"Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Weir S","year":"2003","unstructured":"WeirSMaconeADonatelliJTrieberCTaylorDETanakaSKLevySB. 2003. The mechanism of action of PTK 0796, abstr 2473, poster F-751. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_18_2","volume-title":"Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Weir S","year":"2003","unstructured":"WeirSMaconeADonatelliJTrieberCTaylorDETanakaSKLevySB. 2003. The activity of PTK 0796 against tetracycline resistance, abstr 2611, poster F-752. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_19_2","volume-title":"Approved standard M07-A05","author":"Clinical and Laboratory Standards Institute","year":"2000","unstructured":"Clinical and Laboratory Standards Institute. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M07-A05. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_20_2","first-page":"383","volume-title":"Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases","author":"Flamm RK","year":"2012","unstructured":"FlammRKFarrellDJSaderHSJonesRN. 2012. Antimicrobial activity of PTK 0796 (omadacycline) and comparator agents against contemporary pathogens commonly associated with community acquired respiratory tract infections collected during 2011 from the European Union, abstr P01449, p 383\u2013384. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland."},{"key":"e_1_3_2_21_2","first-page":"384","volume-title":"Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases","author":"Sader HS","year":"2012","unstructured":"SaderHSFlammRKJonesRN. 2012. Antimicrobial activity of PTK 0796 (Omadacycline) tested against gram-positive organisms isolated from European Hospitals in 2011, abstr P1450, p 384. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland."},{"key":"e_1_3_2_22_2","volume-title":"Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Craig WA","year":"2006","unstructured":"CraigWAAndesDOdinecsA. 2006. In vivo pharmacodynamics of MK-2764\/PTK 0796 against various gram-positive and gram-negative bacteria in the thighs of neutropenic and normal mice, abstr 1875, poster F1-1974. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_23_2","first-page":"1074","volume-title":"Abstr. 21st Eur. Congr. Clin. Microbiol. Infect. Dis.","author":"Leahy RG","year":"2011","unstructured":"LeahyRGHanleyBMaconeABDraperMPTanakaSK. 2011. Comparative efficacy of omadacycline (PTK796) in lethal Streptococcus pneumoniae and Staphylococcus aureus pneumoniae models, abstr 3059, p 1074. Abstr. 21st Eur. Congr. Clin. Microbiol. Infect. Dis., Milan, Italy, 7 to 10 May 2011."},{"key":"e_1_3_2_24_2","volume-title":"Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Tessier PR","year":"2006","unstructured":"TessierPRFanHWTanakaSKNicolauDP. 2006. Pharmacokinetic\/pharmacodynamic profile of MK-2764\/PTK 0796 against S. pneumoniae in a murine pneumonia model, abstr 1888, poster F1-1973. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_25_2","volume-title":"Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Yu D","year":"2010","unstructured":"YuDKelleyKAOsbornMNTrzaskoAPettifordSMcKenneyDBradfordPA. 2010. Efficacy of PTK796 in a rat MRSA infective endocarditis (IE) model, abstr B-069. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_26_2","volume-title":"Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Arbeit RD","year":"2008","unstructured":"ArbeitRDRobertsJAForsytheARJohnstonSMSeyediFPukshanskyMTanakaSK. 2008. Safety and efficacy of PTK 0796: Results of the phase 2 study in complicated skin and skin structure infections following IV and oral step down therapy, abstr L-1515b. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_27_2","first-page":"123","volume-title":"Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases","author":"Noel GJ","year":"2012","unstructured":"NoelGJDraperMHaitHTanakaSK. 2012. Safety and efficacy of PTK 0796 (Omadacycline) as treatment of complicated skin and soft tissue infection (cSSTI), abstr P694, p 123\u2013124. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland."},{"key":"e_1_3_2_28_2","first-page":"374","volume-title":"Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases","author":"Sun H","year":"2012","unstructured":"SunHTingLMaiettaRMachineniSPraestgaardJKuemmellASteinDSSunkaraGKovacsSJDraperMP. 2012. A single-dose study to evaluate the pharmacokinetics, safety, and tolerability of multiple formulations of PTK 0796 in healthy subjects, abstr P1423, p 374\u2013375. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland."},{"key":"e_1_3_2_29_2","volume-title":"Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Ting L","year":"2010","unstructured":"TingLSunHKovacsSJKlausnerKTanakaSK. 2010. Pharmacokinetics of intravenous and oral PTK796, a new aminomethylcycline antibiotic, abstr K-124. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1006\/mcpr.2001.0363"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/B978-012775390-4\/50153-6","volume-title":"Handbook of animal models of infection","author":"Frimodt-Moller N","year":"1999","unstructured":"Frimodt-MollerNKnudsenJDEspersenF. 1999. Chapter 14: The mouse peritonitis\/sepsis model, p 127\u2013136. In ZakOSandeMA (ed), Handbook of animal models of infection. Academic Press, London, United Kingdom."},{"key":"e_1_3_2_32_2","volume-title":"Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Cannon EP","year":"2003","unstructured":"CannonEPWhiteNMChaturvediPEspositoCKoromaJTanakaSK. 2003. Phamacokinetics of PTK 0796 in mouse, rat and cynomolgus monkey, abstr 2655, poster F-759. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_33_2","volume-title":"Abstr. 21st Eur. Congr. Clin. Microbiol. Infect. Dis.","author":"Hait H","year":"2011","unstructured":"HaitHArbeitRMolnarDNoelGJTanakaSK. 2011. In a phase 2 complicated skin and soft tissue infections (cSSTI) trial outcomes assessed early in the course of therapy were consistent with outcomes assessed 10\u201317 days after completing therapy for patients treated with either omadacycline (OMC; PTK796) or linezolid, abstr P1528. Abstr. 21st Eur. Congr. Clin. Microbiol. Infect. Dis., Milan, Italy, 7 to 10 May 2011."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.06.011"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(09)70005-6"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1086\/431673"},{"key":"e_1_3_2_37_2","volume-title":"Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology","author":"Chaturvedi P","year":"2003","unstructured":"ChaturvediPEspositoCKoromaJCannonEPTanakaSK. 2003. In vitro assessment of plasma protein binding and metabolic stability of PTK 0796, abstr 2675, poster F-760. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00948-12"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1086\/340400"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543780903505092"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1086\/591861"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.15.1763"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2010.08.004"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01242-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01242-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:35:12Z","timestamp":1645482912000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01242-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1128\/AAC.01242-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.01242-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"2013-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-01-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}